Overview

Cyclin-dependent kinase 9 (CDK9) is a gene that encodes a member of a protein complex that is an elongation factor for RNA polymerase II-directed transcription. Missense mutations, silent mutations, and frameshift insertions are observed in cancers such as colon cancer, skin cancer, and endometrial cancer.

CDK9 is altered in 0.73% of all cancers with colon adenocarcinoma, endometrial endometrioid adenocarcinoma, lung adenocarcinoma, high grade ovarian serous adenocarcinoma, and breast invasive ductal carcinoma having the greatest prevalence of alterations [3].

The most common alterations in CDK9 are CDK9 Mutation (0.58%), CDK9 Amplification (0.07%), CDK9 P286L (0.03%), CDK9 G326D (0.02%), and CDK9 K24R (0.02%) [3].

References

1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.